Research prototype, not medical advice.

04 — Loss of proteostasis

Primary hallmark ("damage") according to López-Otín et al., Cell 2023 (doi:10.1016/j.cell.2022.11.001).

1. Definition

Age-related decline of the network that ensures the cell's proteins are made, folded into the right shape, repaired and destroyed when damaged. Result: accumulation of misfolded proteins and toxic aggregates. Aggregation diseases (Alzheimer's, Parkinson's, ALS, amyloidoses) are its most visible manifestation (Hipp 2019, doi:10.1038/s41580-019-0101-y; Labbadia & Morimoto 2015, doi:10.1146/annurev-biochem-060614-033955).

In plain terms: proteins are the cell's "machines". To work, they must fold like a precise origami. "Assistants" (chaperones) help with folding, "shredders" (proteasome, lysosome) recycle the failed pieces. With age, assistants and shredders run out of steam: the failed origamis pile up and form clumps that clog the cell.

2. Mechanisms and sources

The proteostasis network comprises about 2,000 proteins organised in three branches (Hipp 2019):

What happens with age

3. Symptoms and clinical manifestations

Human evidence comes mainly from misfolding diseases ("proteinopathies", more than 50 diseases; Chiti & Dobson 2017, doi:10.1146/annurev-biochem-061516-045115), whose risk soars with age:

DiseaseAggregating proteinLink with age
Alzheimer's diseaseAmyloid-β, tauRisk roughly doubling every 5 years after 65
Parkinson's diseaseα-synucleinAge = main risk factor
ALS (Charcot disease)TDP-43, SOD1, FUSPeak after 60
Huntington's diseaseHuntingtin (polyglutamine expansion)Genetic; onset in adulthood
Transthyretin amyloidosis (ATTR)Transthyretin (TTR)"Wild-type" form common beyond 75, a cause of heart failure
CataractLens crystallinsAlmost universal with age

Genetic forms: mutations that make a protein more unstable (e.g. APP, PSEN1 for Alzheimer's; TTR for hereditary amyloidosis) bring forward the age of disease, which shows that aggregation is causal for these diseases (Chiti & Dobson 2017).

Lysosomal diseases: Niemann-Pick disease type C (accumulation of lipids in lysosomes) illustrates the link between chaperones and lysosomes (Kirkegaard 2010, doi:10.1038/nature08710).

4. Interactions with the other hallmarks

Hallmark (2023 numbering)Link with loss of proteostasis
1. Genomic instabilityMutations and errors → defective proteins; repair proteins depend on chaperones.
2. Telomere attritionMostly indirect link, through senescence.
3. Epigenetic alterationsChromatin regulates the expression of chaperones and HSF-1.
5. Disabled macroautophagyMain route for clearing large aggregates; the two hallmarks reinforce each other (file 05).
6. Deregulated nutrient sensingmTOR drives protein production; inhibiting it reduces the load and activates autophagy. The insulin/IGF-1 pathway acts through DAF-16 and HSF-1 in the worm (Hsu 2003).
7. Mitochondrial dysfunctionLess ATP for chaperones and the proteasome; misfolded mitochondrial proteins → UPR-mt; aggregates that damage mitochondria.
8. Cellular senescenceAggregates and reticulum stress can trigger senescence.
9. Stem cell exhaustionStem cells maintain enhanced proteostasis; its loss reduces their regenerative capacity.
10. Altered intercellular communicationSpread of aggregates from cell to cell (Jucker & Walker 2013); stress signals transmitted between tissues in the worm.
11. Chronic inflammationAggregates activate microglia and the NLRP3 inflammasome.
12. DysbiosisIn animals: the bacterial amyloid curli accelerates α-synuclein aggregation (old rats; Chen 2016, doi:10.1038/srep34477); the microbiota worsens motor deficits in a mouse model of Parkinson's (Sampson 2016, doi:10.1016/j.cell.2016.11.018); pathological α-synuclein injected into the gut reaches the brain through the vagus nerve (Kim 2019, doi:10.1016/j.neuron.2019.05.035). The hypothesis that Parkinson's starts in the gut is not demonstrated in humans.

5. Existing or investigational remedies

InterventionTargetLevel of evidenceKey resultSource
TafamidisStabilises TTR (prevents its dissociation)Approved (cardiac ATTR)Phase 3 trial: lower all-cause mortality and fewer cardiovascular hospitalisationsMaurer 2018, doi:10.1056/NEJMoa1805689
Patisiran (interfering RNA)Reduces TTR productionApproved (hereditary ATTR, neuropathy)Phase 3: improvement of neuropathy and quality of life vs placeboAdams 2018, doi:10.1056/NEJMoa1716153
NTLA-2001 (in vivo CRISPR-Cas9 editing)Inactivates the TTR gene in the liverHuman phase 1 trialA single infusion: mean TTR reduction of ~87 % at the 0.3 mg/kg doseGillmore 2021, doi:10.1056/NEJMoa2107454
Lecanemab (antibody)Clears amyloid-β protofibrilsApproved (early Alzheimer's)Phase 3: clinical decline slowed by 27 % over 18 months; side effects (brain oedema and microbleeds, ARIA)van Dyck 2023, doi:10.1056/NEJMoa2212948
Donanemab (antibody)Amyloid plaquesApproved (early Alzheimer's)Phase 3: decline slowed by about a third in patients with low/intermediate tau load; ARIASims 2023, doi:10.1001/jama.2023.13239
ArimoclomolAmplifies the chaperone response (HSP70)Approved by the FDA on 20 September 2024 (Miplyffa, with miglustat, Niemann-Pick C) (FDA press release)Phase 2/3: slower progression vs placeboMengel 2021, doi:10.1002/jimd.12428; mechanism: Kirkegaard 2010
Sodium phenylbutyrate + taurursodiol (AMX0035)Reticulum and mitochondrial stressPositive phase 2; negative phase 3 (PHOENIX), withdrawn from the market in 2024Phase 2: slower functional decline in ALS; not confirmed afterwardsPaganoni 2020, doi:10.1056/NEJMoa1916945; withdrawal announced on 4 April 2024 after the failure of PHOENIX (Amylyx press release; Federal Register 2025)
ISRIBReleases the brake of the integrated stress responsePreclinical (mice)Improves memory (Sidrauski 2013); reverses age-related memory decline in old mice (Krukowski 2020)doi:10.7554/eLife.00498; doi:10.7554/eLife.62048
Restoring CMA (LAMP2A)Chaperone-mediated autophagyPreclinical (transgenic mice)Better liver function in old miceZhang & Cuervo 2008
Rapamycin, caloric restrictionmTOR → less synthesis, more autophagySolid preclinical; human trials (see file 05)Indirect effects on proteostasisHipp 2019

Finding: real clinical successes concern diseases targeting a single protein (TTR, amyloid-β), with clear benefits for ATTR but modest ones for Alzheimer's. No intervention strengthens the proteostasis network as a whole in humans.

6. Open questions

  1. Aggregates: cause or defence? Large aggregates could be a way of "storing away" more toxic forms (oligomers). Clearing plaques brings only a modest benefit in Alzheimer's.
  2. Global vs targeted intervention: can HSF-1, the proteasome or CMA be boosted in humans without risk (cancers also use these networks to survive)?
  3. Biomarkers: how to measure proteostasis in a living person, outside specific imaging (amyloid PET) or blood markers (p-tau)?
  4. Translation from the worm: most causal evidence on longevity comes from C. elegans (David 2010; Walther 2015; Hsu 2003).
  5. Timing of intervention: anti-amyloid trials suggest acting early, before symptoms.

7. References

  1. López-Otín C, et al. Hallmarks of aging: an expanding universe. Cell 2023. doi:10.1016/j.cell.2022.11.001
  2. Hipp MS, Kasturi P, Hartl FU. The proteostasis network and its decline in ageing. Nat Rev Mol Cell Biol 2019. doi:10.1038/s41580-019-0101-y
  3. Labbadia J, Morimoto RI. The biology of proteostasis in aging and disease. Annu Rev Biochem 2015. doi:10.1146/annurev-biochem-060614-033955
  4. Kaushik S, Cuervo AM. Proteostasis and aging. Nat Med 2015. doi:10.1038/nm.4001
  5. Kaushik S, Cuervo AM. The coming of age of chaperone-mediated autophagy. Nat Rev Mol Cell Biol 2018. doi:10.1038/s41580-018-0001-6
  6. David DC, et al. Widespread protein aggregation as an inherent part of aging in C. elegans. PLoS Biol 2010. doi:10.1371/journal.pbio.1000450
  7. Walther DM, et al. Widespread proteome remodeling and aggregation in aging C. elegans. Cell 2015. doi:10.1016/j.cell.2015.03.032
  8. Jucker M, Walker LC. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 2013. doi:10.1038/nature12481
  9. Hsu AL, Murphy CT, Kenyon C. Regulation of aging and age-related disease by DAF-16 and heat-shock factor. Science 2003. doi:10.1126/science.1083701
  10. Zhang C, Cuervo AM. Restoration of chaperone-mediated autophagy in aging liver improves cellular maintenance and hepatic function. Nat Med 2008. doi:10.1038/nm.1851
  11. Chiti F, Dobson CM. Protein misfolding, amyloid formation, and human disease: a summary of progress over the last decade. Annu Rev Biochem 2017. doi:10.1146/annurev-biochem-061516-045115
  12. Kirkegaard T, et al. Hsp70 stabilizes lysosomes and reverts Niemann-Pick disease-associated lysosomal pathology. Nature 2010. doi:10.1038/nature08710
  13. Maurer MS, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. NEJM 2018. doi:10.1056/NEJMoa1805689
  14. Adams D, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. NEJM 2018. doi:10.1056/NEJMoa1716153
  15. Gillmore JD, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. NEJM 2021. doi:10.1056/NEJMoa2107454
  16. van Dyck CH, et al. Lecanemab in early Alzheimer's disease. NEJM 2023. doi:10.1056/NEJMoa2212948
  17. Sims JR, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 2023. doi:10.1001/jama.2023.13239
  18. Mengel E, et al. Efficacy and safety of arimoclomol in Niemann-Pick disease type C: results from a double-blind, randomised, placebo-controlled, multinational phase 2/3 trial. J Inherit Metab Dis 2021. doi:10.1002/jimd.12428
  19. Paganoni S, et al. Trial of sodium phenylbutyrate–taurursodiol for amyotrophic lateral sclerosis. NEJM 2020. doi:10.1056/NEJMoa1916945
  20. Sidrauski C, et al. Pharmacological brake-release of mRNA translation enhances cognitive memory. eLife 2013. doi:10.7554/eLife.00498
  21. Krukowski K, et al. Small molecule cognitive enhancer reverses age-related memory decline in mice. eLife 2020. doi:10.7554/eLife.62048
  22. Chen SG, et al. Exposure to the functional bacterial amyloid protein curli enhances alpha-synuclein aggregation in aged Fischer 344 rats and Caenorhabditis elegans. Sci Rep 2016. doi:10.1038/srep34477
  23. Sampson TR, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell 2016. doi:10.1016/j.cell.2016.11.018
  24. Kim S, et al. Transneuronal propagation of pathologic α-synuclein from the gut to the brain models Parkinson's disease. Neuron 2019. doi:10.1016/j.neuron.2019.05.035
  25. FDA. FDA approves first treatment for Niemann-Pick disease, type C (2024). https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-niemann-pick-disease-type-c
  26. Amylyx Pharmaceuticals. Formal intention to remove RELYVRIO/ALBRIOZA from the market (4 avril 2024). https://www.amylyx.com/news/amylyx-pharmaceuticals-announces-formal-intention-to-remove-relyvrior/albriozatm-from-the-market-provides-updates-on-access-to-therapy-pipeline-corporate-restructuring-and-strategy

DOIs verified via the Crossref API on 2026-10-19.